0.79
-0.1888(-19.29%)
Currency In USD
| Previous Close | 0.98 |
| Open | 0.87 |
| Day High | 0.89 |
| Day Low | 0.75 |
| 52-Week High | 3.07 |
| 52-Week Low | 0.73 |
| Volume | 710,756 |
| Average Volume | 116,729 |
| Market Cap | 30.83M |
| PE | -1.8 |
| EPS | -0.44 |
| Moving Average 50 Days | 0.96 |
| Moving Average 200 Days | 1.25 |
| Change | -0.19 |
If you invested $1000 in SCYNEXIS, Inc. (SCYX) 10 years ago, it would be worth $8.78 as of May 18, 2025 at a share price of $0.79. Whereas If you bought $1000 worth of SCYNEXIS, Inc. (SCYX) shares 5 years ago, it would be worth $100.13 as of May 18, 2025 at a share price of $0.79.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
SCYNEXIS to Present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
GlobeNewswire Inc.
Apr 08, 2025 12:00 PM GMT
JERSEY CITY, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation
SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections
GlobeNewswire Inc.
Dec 18, 2024 1:00 PM GMT
JERSEY CITY, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it has comple
SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire Inc.
Nov 06, 2024 9:30 PM GMT
Clinical study reports for the FURI, CARES and NATURE trials in refractory or resistant invasive fungal infections were delivered to GSK, triggering a $10 million development milestone payment to SCYNEXIS, received in Q3 2024. SCY-247 preclinical stu